FAQ on Clene's Submission of Briefing Book to FDA for CNM-Au8 in ALS Treatment

What is Clene submitting to the FDA?

Clene is submitting a briefing book to the FDA regarding its new drug application (NDA) for CNM-Au8 as a potential treatment for ALS, including analyses of clinical study data to address previous FDA comments.

Why is the submission of the briefing book significant?

This submission is significant because it represents a step towards potential accelerated approval of CNM-Au8 for ALS treatment, demonstrating the drug’s mechanism of action and its potential to improve clinical outcomes for ALS patients.

How does CNM-Au8 work?

CNM-Au8 is an investigational therapy that improves the survival and function of central nervous system cells by targeting mitochondrial function and the NAD pathway, while reducing oxidative stress.

When does Clene anticipate submitting the briefing book?

Clene anticipates submitting the briefing book by July 13, 2024, in advance of a Type C interaction with the FDA.

What is the purpose of the Type C interaction with the FDA?

The purpose is to obtain key feedback from the FDA on the potential path to submission of an NDA for CNM-Au8 as a treatment for ALS.

Where can I find more information about Clene and CNM-Au8?

More information can be found on Clene’s website at www.Clene.com and in the full press release at https://ibn.fm/PzwfB.

Who is involved in this submission?

Clene Inc. and its wholly owned subsidiary, Clene Nanomedicine Inc., are involved in preparing and submitting the briefing book to the FDA.

What are the implications of this submission for ALS patients?

If approved, CNM-Au8 could offer a new treatment option for ALS patients, potentially improving survival and clinical outcomes by targeting mitochondrial health and neuronal function.

How does CNM-Au8 compare to other ALS treatments?

The content does not provide a direct comparison to other ALS treatments, but CNM-Au8 is described as a first-in-class therapy focusing on mitochondrial health and neuronal function, which may offer a unique mechanism of action.

What should investors know about this development?

Investors should note that this submission is a critical step towards potential FDA approval of CNM-Au8 for ALS, which could significantly impact Clene’s future and the treatment landscape for neurodegenerative diseases.